Press releases
- Novocure to Report Second Quarter 2024 Financial Results
- METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival
- TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany
- Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
- Novocure Reports First Quarter 2024 Financial Results
- Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
More ▼
Key statistics
As of last trade, Novocure Ltd (038:FRA) traded at 17.18, 70.39% above the 52 week low of 10.08 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 17.18 |
---|---|
High | 17.18 |
Low | 17.18 |
Bid | 17.16 |
Offer | 17.46 |
Previous close | 16.77 |
Average volume | 382.33 |
---|---|
Shares outstanding | 107.61m |
Free float | 97.64m |
P/E (TTM) | -- |
Market cap | 2.06bn USD |
EPS (TTM) | -1.81 USD |
Data delayed at least 15 minutes, as of Jul 23 2024 07:10 BST.
More ▼